BlackRock
PLYX

BlackRock’s Polaryx Therapeutics Inc PLYX Stock Holding History

BlackRock’s Portfolio PLYX Stock Details PLYX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$109K Hold
41,012
– – ﹤0.01% 4983
2026
Q1 		$310K Buy
+41,012
New +$265K ﹤0.01% 4642

Other funds holding PLYX

Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
HF
HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
AF
Allworth Financial Folsom, California $23.6B AUM 20.99% 1-Year Est. Return
Vanguard Global Advisers
Vanguard Global Advisers Malvern, Pennsylvania $215B AUM
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

BlackRock's PLYX Position: Q2 2026 in Review

BlackRock held its Polaryx Therapeutics Inc (PLYX) position steady in Q2 2026 at 41,012 shares worth $109K. The position accounts for ﹤0.01% of the portfolio, ranked #4983.

BlackRock first reported a position in PLYX in Q1 2026 and has held it in 2 quarters since. The position peaked at $310K in Q1 2026. 13 funds tracked by Wall St. Rank hold PLYX as of Q2 2026.

  • BlackRock held 41,012 shares of Polaryx Therapeutics Inc worth $109K as of Q2 2026.
  • BlackRock left its Polaryx Therapeutics Inc share count unchanged in Q2 2026.
  • Polaryx Therapeutics Inc made up ﹤0.01% of BlackRock's portfolio in Q2 2026, its #4983 holding.
  • BlackRock first reported a position in Polaryx Therapeutics Inc in Q1 2026 and has held it in 2 quarters since.
  • BlackRock's Polaryx Therapeutics Inc position peaked at $310K in Q1 2026.
  • 13 funds tracked by Wall St. Rank held Polaryx Therapeutics Inc as of Q2 2026.

Based on BlackRock's 13F filing for Q2 2026, filed 7 Aug 2026.